Skip to content

Comparison of Programmed Intermittent Epidural Bolus With Continuous Epidural Infusion for Labor Epidural Analgesia

Comparison of Programmed Intermittent Epidural Bolus With Continuous Epidural Infusion for Labor Epidural Analgesia

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02873091
Enrollment
186
Registered
2016-08-19
Start date
2016-09-30
Completion date
2017-10-31
Last updated
2016-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Labor Analgesia

Brief summary

Sixteen million babies were born in 2010, approximately half were by cesarean. Labor analgesia should be the first choice for these parturients based on the consideration of security and humanization. However this labor analgesia rate is quite low in China (\<5%) while in western country, this rate is up to 60%. Programmed intermittent epidural bolus (PIEB) is the latest technique for labor analgesia which has less neurotoxicity theoretically compared with Continuous Epidural Infusion(CEI) with Patient controlled epidural analgesia (PCEA) which is used most commonly. In that study, they reported less total local anesthetic consumption, fewer manual bolus doses and greater patient satisfaction with the PIEB technique. In China, multiple factors contribute to the reasons of low labor analgesia rate. From the patient's point of view, worrying about unsatisfied analgesia, and not adapted to the symptoms of motor block, such as inability to move their legs distressing, both are important reasons of refusing labor analgesia and preferring to cesarean delivery. Therefore, in this clinical trial, we plan to find a safer and more effective regimen for labor analgesia in Chineseparturients. This clinical trial is designed to prove PIEB used Ropivacaine is safer and more effective than CEI for labor analgesia in Chinese parturients.

Interventions

PROCEDUREEpidural analgesia
DRUGropivacaine
DRUGsufentanil

Sponsors

Nanjing Maternity and Child Health Care Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
22 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Subjects who agree to join this study * Age: 22y-40y * American Society of Anesthesiologists (ASA) physical status 1 or 2 * Gestation : 37-41 weeks * Primipara * Singleton fetus and head presentation * In early labor: cervical dilation for 1-3cm * Requesting labor epidural analgesia

Exclusion criteria

* Contraindication for epidural analgesia * Height less than 150 cm or more than 170 cm * Morbid obesity (BMI more than 35) * High-risk pregnancy:(gestational diabetes mellitus, gestational hypertension, placenta previa, placental abruption, preeclampsia) * Received parenteral opioids * Unable to perform motor block evaluation tests

Design outcomes

Primary

MeasureTime frameDescription
Maternal visual analogue scale (VAS)At time of initiation of analgesia and hourly thereafter until 1 hours postpartum (approximately 10 hours)a visual analog scale (VAS) with a 10 cm vertical score ranged from no pain to worst possible pain

Secondary

MeasureTime frame
Maternal modified Bromage scaleAt time of initiation of analgesia and hourly thereafter until 2 hours postpartum (approximately 10 hours)
Subject's Satisfaction with labor epidural analgesiaAt the time after childbirth
Total ropivacaine and sufentanil consumptionAt two hours postpartum
Proportion of parturients requiring additional PCEA bolusesAt two hours postpartum
Rate of very satisfiedand/or satisfied,Proportion of subjects who has experienced Visual analog scale (VAS) score for pain more than 3 scaleAt two hours postpartum
Maternal heart rateAt time of initiation of analgesia and hourly thereafter until 4 hours postpartum (approximately 12 hours)
Rates of cesarean delivery and instrument-assisted deliveryAt time of placental delivery
Duration of analgesiaInitiation of analgesia to 2 h postpartum (approximately 10 hours)
Maternal respiratory rateAt time of initiation of analgesia and hourly thereafter until 4 hours postpartum (approximately 12 hours)
Use of oxytocin after analgesiaAt twenty-four hours postpartum
Incidence of maternal side effectsInitiation of analgesia to 2 hour postpartum (approximately 10 hours)
Neonatal Apgar scaleAt the first and fifth minutes after baby was born
Fetal heart rateFrom initiation of analgesia to delivery (approximately 8 hours)
Neonatal weightAt delivery
Mean number of PCEAAt two hours postpartum
Maternal blood pressureAt time of initiation of analgesia and hourly thereafter until 4 hours postpartum (approximately 12 hours)
Durations of labor stagesFrom the beginning of regular contraction of uterus to the end of the labor (approximately 12 hours)

Countries

China

Contacts

Primary ContactCaijuan Li, M.A.
licaijuanyumi1228@126.com025-52226112

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026